Who is sponsoring NCT07118319?

NCT07118319 is sponsored by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd..

What drugs are being tested in NCT07118319?

Interventions in NCT07118319: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN), Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN).

What condition does NCT07118319 study?

NCT07118319 studies Amyotrophic Lateral Sclerosis (ALS).

Is NCT07118319 still recruiting?

NCT07118319 is currently recruiting now. Last updated 21 November 2025.

Last reviewed 2025-11-21 · How we verify

NCT07118319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Recruiting now Phase 1 Last updated 21 November 2025

What this trial tests

Phase 1 trial testing Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Amyotrophic Lateral Sclerosis (ALS) in 12 participants. Currently enrolling.

Timeline

15 September 2025

Primary endpoint
31 January 2027

30 September 2028

Quick facts

Lead sponsor	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	15 September 2025
Primary completion	31 January 2027
Estimated completion	30 September 2028
Sites	1 location across China

Drugs / interventions tested

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

Conditions studied

Amyotrophic Lateral Sclerosis (ALS) — all drugs for Amyotrophic Lateral Sclerosis (ALS) →

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Amyotrophic Lateral Sclerosis (ALS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Amyotrophic Lateral Sclerosis (ALS)

Currently open trials in the same condition.

NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
NCT07187388 — Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neu · NA · recruiting
NCT07233148 — Healing ALS Registry Observational Study (HAROS) · recruiting
NCT07257302 — Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis · NA · recruiting
NCT07202494 — Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and · recruiting

Other XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. trials

Trials by the same sponsor.

NCT06974968 — Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Tri · Phase 2 · not yet recruiting
NCT07166757 — Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease · Phase 1, PHASE2 · recruiting
NCT07080775 — The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease · Phase 1 · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07118319 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Last refreshed: 21 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07118319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing